Effect of fumaric acid, its dimethylester, and topical antipsoriatic drugs on epidermal differentiation in the mouse tail model

Skin Pharmacology and Physiology

Volumn 9, Issue 2, 1996, Pages 99-103

  Sebok B ^a   Szabados, T ^a   Kerenyi M ^a   Schneider, I ^a   Mahrle, G ^b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Dithranol derivative; Fumaric acid; Mouse tail test; Psoriasis vulgaris

Indexed keywords

ANTIPSORIASIS AGENT; BETAMETHASONE; BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; DITHRANOL; DITHRANOL DERIVATIVE; FUMARIC ACID; FUMARIC ACID DIMETHYL ESTER; SALICYLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; EPIDERMIS CELL; KERATOSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TAIL; TISSUE SECTION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; CELL DIFFERENTIATION; EPIDERMIS; FUMARATES; KERATOSIS; MALE; MICE; PSORIASIS; TAIL;

EID: 0029965691     PISSN: 16605527     EISSN: 16605535     Source Type: Journal    
DOI: 10.1159/000211404     Document Type: Article

References (23)

1. Camp RDR: Psoriasis; in Champion RH, Burton JL, Ebling FJG (eds): Textbook of Dermatology, ed 5. Oxford, Blackwell, 1992, pp 1391-1457.
2. Krueger GG, Manning DD, Malouf J, Ogden B: Long-term maintenance of psoriatic human skin on congenitally athymic mice. J Invest Dermatol 1975;64:307-312.
3. Vivier AD, Stoughton RB: An animal model for screening topical and systemic drugs for potential use in the treatment of psoriasis. J Invest Dermatol 1975;65:235-237.
4. McCullough JL, Schreiber SH, Zi-boh VA: Cell proliferation kinetics of epidermis in the essential fatty acid deficient rats. J Invest Dermatol 1978;70:318-320.
5. Lowe NJ, Stoughton RB: Essential fatty acid deficient hairless mouse: A model of chronic epidermal hyperproliferation. Br J Dermatol 1977;96:155-162.
6. Boehncke WH, Stcrry W, Hainzl A, et al: Psoriasiform architecture of murine epidermis overlying human psoriatic dermis transplanted onto SCID mice. Arch Dermatol Res 1994;286:325-330.
7. Marks R, Pongsehirun D, Saylan T: A method for the assay of topical corticosteroids. Br J Dermatol 1973; 88:69-74.
8. Sundberg JP, Dunstan RW, Roop DR, Beamer WG: Full thickness skin grafts from flaky skin mice to nude mice: Maintenance of the psoriasiform phenotype. J Invest Dermatol 1994;102:781-788.
9. Jarrett A, Spearman RIG: Psoriasis; in Taverner D, Trounce J (eds): Histochemistry of the Skin. London, University Press, 1964.
10. Bosman B, Matthiesen T, Hess V, Friderichs E: A quantitative method for measuring antipsoriatic activity of drugs by the mouse tail test. Skin Pharmacol 1992;5:41-48.
11. Bosman B: Testing of lipoxygenase inhibitors, cyclooxygenase inhibitors, drugs with immunomodulating properties and some reference antipsoriatic drugs in the modified mouse tail test, an animal model of psoriasis. Skin Pharmacol 1994:7: 324-334.
12. Hofbauer M, Dowd PM, Atkinson J, et al: Evaluation of a therapeutic concentration of dithranol in the mouse-tail test. Br J Dermatol 1988; 118:85-89.
13. Bonnekoh B, Tänzer H, Seidel M, et al: Structure-function relationship of new anthralin derivatives assayed for growth inhibition and cytotoxicity in human keratinocyte cultures. Arch Pharm (Weinheim) 1991;324: 899-906.
14. Sebök B, Bonnekoh B, Geisel J, Mahrle G: Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivatives in keratinocyte cultures. Eur J Pharmacol 1994; 270:79-87.
15. Mann HB, Whitney DR: On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 1947; 18:50-60.
16. Nugteren-Huying WM, van der Schroeff JG, Hermans J, Suurmond D: Fumaric acid therapy for psoriasis: A randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 1990,22:311-312.
17. Altmeyer PJ, Matthes U, Pawlak F, et al: Antipsoriatic effect of fumaric acid derivatives. J Am Acad Dermatol 1994:30:977-981.
18. Skaria AM, Schmid UH: Topische Behandlung mit Fumarsalbe 3%: Eine klinisch-histopathologische Studie. Z Hautkr 1993;68:321-322.
19. Haan de P, Blombergvan der Flier BME, Groot de J, et al: The risk of sensibilization and contact urticaria upon topical application of fumaric acid derivatives. Dermatology 1994; 188:126-130.
20. Berth-Jones J, Fletcher A, Hutchinson PE: Epidermal cytokeratin and immunocyte responses during treatment of psoriasis with calcipotriol; in Norman AW, Bouillon R, Tho-masset M (eds): Vitamin D: Gene Regulation, Structure-Function Analysis, Clinical Applications. Berlin, de Gruyter, 1991, pp 424-425.
21. Jong de EMGJ, van Vlijmen JMMJ, van Erp PEJ, et al: Keratin 17: A useful marker in antipsoriatic therapies. Arch Dermatol Res 1991:283: 480-482.
22. Lützow-Holm C, Huitfeldts H, Brandtzaun P, Clausen OPE: 1,25-Dihydroxyvitamin Ds and the vitamin D analogue KH 1060 induce hypcrproliferation in normal mouse epidermis. J Invest Dermatol 1992; 98:525A.
23. Thieroff-Ekerdt R, Gerhard D, Krause A, Wiesinger H: 1,25-Dihy-droxyvitamin D3 induces epidermal hyperplasia in normal mouse skin. J Invest Dermatol 1993;100:592A.